A phase I multi-dose study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in adults with primary or secondary acute myeloid leukemia (AML) in morphologic complete remission with minimal residual disease (MRD)

Contact:

NCT Number:

Protocol:

AAAS8676

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease. CYNK-001 has not been approved by the FDA for the treatment of cancer or any other disease and its use in this study is investigational. About 22 patients in the US will take part in this study.

Are you Eligible? (Inclusion Criteria)

  • Are you ≥ 18 and ≤ 75 years of age?
  • Do you have newly diagnosed of Acute Myeloid Leukemia (AML)?
  • Have you ever receive induction and/or consolidation therapy?

Specialty Area(s)

Leukemia, Acute Myeloid Leukemia

Principal Investigator

Profile Headshot
  • Director, Hematologic Malignancies Section